Targeting Senescent Alveolar Epithelial Cells Using Engineered Mesenchymal Stem Cell-Derived Extracellular Vesicles To Treat Pulmonary Fibrosis

Overview

Journal ACS Nano

Publisher American Chemical Society

Specialty Biotechnology

Date 2024 Feb 21

PMID 38381372

Authors

Yaoying Long

Bianlei Yang

Qian Lei

Fei Gao

Li Chen

Wenlan Chen

Siyi Chen

Wenxiang Ren

Yulin Cao

Liuyue Xu

Di Wu

Jiao Qu

He Li

Yali Yu

Anyuan Zhang

Shan Wang

Weiqun Chen

Hongxiang Wang

Ting Chen

Zhichao Chen

Qiubai Li

Affiliations

Soon will be listed here.

Abstract

Type 2 alveolar epithelial cell (AEC2) senescence is crucial to the pathogenesis of pulmonary fibrosis (PF). The nicotinamide adenine dinucleotide (NAD)-consuming enzyme cluster of differentiation 38 (CD38) is a marker of senescent cells and is highly expressed in AEC2s of patients with PF, thus rendering it a potential treatment target. Umbilical cord mesenchymal stem cell (MSC)-derived extracellular vesicles (MSC-EVs) have emerged as a cell-free treatment with clinical application prospects in antiaging and antifibrosis treatments. Herein, we constructed CD38 antigen receptor membrane-modified MSC-EVs (CD38-ARM-MSC-EVs) by transfecting MSCs with a lentivirus loaded with a CD38 antigen receptor-CD8 transmembrane fragment fusion plasmid to target AEC2s and alleviate PF. Compared with MSC-EVs, the CD38-ARM-MSC-EVs engineered in this study showed a higher expression of the CD38 antigen receptor and antifibrotic miRNAs and targeted senescent AEC2s cells highly expressing CD38 in vitro and in naturally aged mouse models after intraperitoneal administration. CD38-ARM-MSC-EVs effectively restored the NAD levels, reversed the epithelial-mesenchymal transition phenotype, and rejuvenated senescent A549 cells in vitro, thereby mitigating multiple age-associated phenotypes and alleviating PF in aged mice. Thus, this study provides a technology to engineer MSC-EVs and support our CD38-ARM-MSC-EVs to be developed as promising agents with high clinical potential against PF.

Citing Articles

Mesenchymal stem cell exosome therapy: current research status in the treatment of neurodegenerative diseases and the possibility of reversing normal brain aging.

Quan J, Liu Q, Li P, Yang Z, Zhang Y, Zhao F Stem Cell Res Ther. 2025; 16(1):76.

PMID: 39985030 PMC: 11846194. DOI: 10.1186/s13287-025-04160-5.

Therapeutic Efficacy and Promise of Human Umbilical Cord Mesenchymal Stem Cell-Derived Extracellular Vesicles in Aging and Age-Related Disorders.

Zhang A, Li Q, Chen Z Int J Mol Sci. 2025; 26(1.

PMID: 39796081 PMC: 11719504. DOI: 10.3390/ijms26010225.

Mesenchymal Stem Cell-Derived Extracellular Vesicles for Regenerative Applications and Radiotherapy.

Wang N, Ma F, Song H, He N, Zhang H, Li J Cell Transplant. 2025; 34():9636897241311019.

PMID: 39780320 PMC: 11713979. DOI: 10.1177/09636897241311019.

Targeting Fibrosis: From Molecular Mechanisms to Advanced Therapies.

Di X, Li Y, Wei J, Li T, Liao B Adv Sci (Weinh). 2024; 12(3):e2410416.

PMID: 39665319 PMC: 11744640. DOI: 10.1002/advs.202410416.

Extracellular Vesicles in Idiopathic Pulmonary Fibrosis: Pathogenesis, Biomarkers and Innovative Therapeutic Strategies.

Yang Y, Lv M, Xu Q, Wang X, Fang Z Int J Nanomedicine. 2024; 19:12593-12614.

PMID: 39619058 PMC: 11606342. DOI: 10.2147/IJN.S491335.

References

Camacho-Pereira J, Tarrago M, Chini C, Nin V, Escande C, Warner G . CD38 Dictates Age-Related NAD Decline and Mitochondrial Dysfunction through an SIRT3-Dependent Mechanism. Cell Metab. 2016; 23(6):1127-1139. PMC: 4911708. DOI: 10.1016/j.cmet.2016.05.006. View

Fang T, Yang J, Liu L, Xiao H, Wei X . Nicotinamide mononucleotide ameliorates senescence in alveolar epithelial cells. MedComm (2020). 2021; 2(2):279-287. PMC: 8491199. DOI: 10.1002/mco2.62. View

Sengupta V, Sengupta S, Lazo A, Woods P, Nolan A, Bremer N . Exosomes Derived from Bone Marrow Mesenchymal Stem Cells as Treatment for Severe COVID-19. Stem Cells Dev. 2020; 29(12):747-754. PMC: 7310206. DOI: 10.1089/scd.2020.0080. View

Desai T, Brownfield D, Krasnow M . Alveolar progenitor and stem cells in lung development, renewal and cancer. Nature. 2014; 507(7491):190-4. PMC: 4013278. DOI: 10.1038/nature12930. View

Drent E, Themeli M, Poels R, de Jong-Korlaar R, Yuan H, de Bruijn J . A Rational Strategy for Reducing On-Target Off-Tumor Effects of CD38-Chimeric Antigen Receptors by Affinity Optimization. Mol Ther. 2017; 25(8):1946-1958. PMC: 5542711. DOI: 10.1016/j.ymthe.2017.04.024. View

Zhao W, Cheng J, Luo Y, Fu W, Zhou L, Wang X . MicroRNA let-7f-5p regulates PI3K/AKT/COX2 signaling pathway in bacteria-induced pulmonary fibrosis via targeting of in forest musk deer. PeerJ. 2022; 10:e14097. PMC: 9547585. DOI: 10.7717/peerj.14097. View

Jayasinghe M, Pirisinu M, Yang Y, Peng B, Pham T, Lee C . Surface-engineered extracellular vesicles for targeted delivery of therapeutic RNAs and peptides for cancer therapy. Theranostics. 2022; 12(7):3288-3315. PMC: 9065173. DOI: 10.7150/thno.68667. View

Xu C, Zhao J, Li Q, Hou L, Wang Y, Li S . Exosomes derived from three-dimensional cultured human umbilical cord mesenchymal stem cells ameliorate pulmonary fibrosis in a mouse silicosis model. Stem Cell Res Ther. 2020; 11(1):503. PMC: 7687745. DOI: 10.1186/s13287-020-02023-9. View

Xu C, Hou L, Zhao J, Wang Y, Jiang F, Jiang Q . Exosomal let-7i-5p from three-dimensional cultured human umbilical cord mesenchymal stem cells inhibits fibroblast activation in silicosis through targeting TGFBR1. Ecotoxicol Environ Saf. 2022; 233:113302. DOI: 10.1016/j.ecoenv.2022.113302. View

10.

Ashcroft T, Simpson J, Timbrell V . Simple method of estimating severity of pulmonary fibrosis on a numerical scale. J Clin Pathol. 1988; 41(4):467-70. PMC: 1141479. DOI: 10.1136/jcp.41.4.467. View

11.

Chen Y, Li X, Li Y, Wu Y, Huang G, Wang X . Downregulation of microRNA‑423‑5p suppresses TGF‑β1‑induced EMT by targeting FOXP4 in airway fibrosis. Mol Med Rep. 2022; 26(1). PMC: 9185700. DOI: 10.3892/mmr.2022.12758. View

12.

Murphy D, de Jong O, Brouwer M, Wood M, Lavieu G, Schiffelers R . Extracellular vesicle-based therapeutics: natural versus engineered targeting and trafficking. Exp Mol Med. 2019; 51(3):1-12. PMC: 6418170. DOI: 10.1038/s12276-019-0223-5. View

13.

Teng F, Fussenegger M . Shedding Light on Extracellular Vesicle Biogenesis and Bioengineering. Adv Sci (Weinh). 2021; 8(1):2003505. PMC: 7788585. DOI: 10.1002/advs.202003505. View

14.

Nadeeshani H, Li J, Ying T, Zhang B, Lu J . Nicotinamide mononucleotide (NMN) as an anti-aging health product - Promises and safety concerns. J Adv Res. 2022; 37:267-278. PMC: 9039735. DOI: 10.1016/j.jare.2021.08.003. View

15.

Longatti A, Schindler C, Collinson A, Jenkinson L, Matthews C, FitzPatrick L . High affinity single-chain variable fragments are specific and versatile targeting motifs for extracellular vesicles. Nanoscale. 2018; 10(29):14230-14244. DOI: 10.1039/c8nr03970d. View

16.

Cho S, Stout-Delgado H . Aging and Lung Disease. Annu Rev Physiol. 2019; 82:433-459. PMC: 7998901. DOI: 10.1146/annurev-physiol-021119-034610. View

17.

Xu Q, Zhang Z, Zhao L, Qin Y, Cai H, Geng Z . Tropism-facilitated delivery of CRISPR/Cas9 system with chimeric antigen receptor-extracellular vesicles against B-cell malignancies. J Control Release. 2020; 326:455-467. DOI: 10.1016/j.jconrel.2020.07.033. View

18.

Ferrantelli F, Arenaccio C, Manfredi F, Olivetta E, Chiozzini C, Leone P . The Intracellular Delivery Of Anti-HPV16 E7 scFvs Through Engineered Extracellular Vesicles Inhibits The Proliferation Of HPV-Infected Cells. Int J Nanomedicine. 2019; 14:8755-8768. PMC: 6844212. DOI: 10.2147/IJN.S209366. View

19.

Usman W, Pham T, Kwok Y, Vu L, Ma V, Peng B . Efficient RNA drug delivery using red blood cell extracellular vesicles. Nat Commun. 2018; 9(1):2359. PMC: 6004015. DOI: 10.1038/s41467-018-04791-8. View

20.

Antes T, Middleton R, Luther K, Ijichi T, Peck K, Liu W . Targeting extracellular vesicles to injured tissue using membrane cloaking and surface display. J Nanobiotechnology. 2018; 16(1):61. PMC: 6116387. DOI: 10.1186/s12951-018-0388-4. View